» Articles » PMID: 34630267

Can High B Value Diffusion Be a Surrogate Marker for PET-A MR/PET Study in Neurooncology Set Up

Overview
Journal Front Neurol
Specialty Neurology
Date 2021 Oct 11
PMID 34630267
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Hybrid whole-body magnetic resonance/positron emission tomography (MR/PET) systems are new diagnostic tools enabling the simultaneous acquisition of morphologic and multiparametric functional data, which allow for a diversified characterization of oncological diseases. This study aimed to compare the diagnostic ability of MRI with the diffusion-weighted image (DWI), and simultaneous integrated positron emission tomography MR/PET to detect malignant lesions and elucidate the utility and limitations of these imaging modalities in preoperative and postoperative follow up in cancer patients. A total of 45 patients undergoing simultaneous MR/PET for CNS ICSOL in our institution between January 2016 and July 2020 were considered in this study. Post-processing was done in Siemens syngo software to generate a b2000 image. This image was then inverted to grayscale and compared with the NAC image of PET. The lesion-based sensitivity, specificity, positive predictive value, and negative predictive value for DWI were 92.3, 83.3, 97.3, and 62.5%, respectively (at 95% CI and was 0.000). The lesion-based sensitivity, specificity, positive predictive value, and negative predictive value for PET were 97.4, 71.4, 94.9, and 83.3%, respectively (at 95% CI and was 0.000). The lesion-based sensitivity and specificity of DWI were comparable with those of PET. Although DWI and FDG-PET reflect different tissue properties, there is an association between the measures of both methods in CNS tumors probably because of the coupling of cellularity with tumor metabolism as seen on FDG and other PET tracers. Our study shows that DWI acts as a surrogate biomarker for FDG PET and other tracers in tumors. The method of DWI image generation is simple, radiation-free, and cost-effective in a clinical setup. The simultaneous DWI-PET study provides evidence and confirms the role of DWI in surveillance imaging of tumors.

Citing Articles

Prospective Study to Evaluate the Role of Dual Point Contrast-enhanced Magnetic Resonance Imaging in Differentiation of Brain Tumoral from Nontumoral Tissue: A Magnetic Resonance/PET Study.

Mangalore S, Pradeep G, Murthy V, Bairwa P, Kumar P, Saini J Indian J Nucl Med. 2024; 39(2):87-97.

PMID: 38989312 PMC: 11232725. DOI: 10.4103/ijnm.ijnm_103_23.

References
1.
Stopa B, Juhasz C, Mittal S . Comparison of Amino Acid PET to Advanced and Emerging MRI Techniques for Neurooncology Imaging: A Systematic Review of the Recent Studies. Mol Imaging. 2021; 2021:8874078. PMC: 8205602. DOI: 10.1155/2021/8874078. View

2.
Qi Y, Liu X, Li J, Yao H, Yuan S . Fluorine-18 labeled amino acids for tumor PET/CT imaging. Oncotarget. 2017; 8(36):60581-60588. PMC: 5601164. DOI: 10.18632/oncotarget.19943. View

3.
Jacob M, Pandit A, Jora C, Mudalsha R, Sharma A, Pathak H . Comparative study of (18)F-DOPA, (13)N-Ammonia and F18-FDG PET/CT in primary brain tumors. Indian J Nucl Med. 2013; 26(3):139-43. PMC: 3543579. DOI: 10.4103/0972-3919.103996. View

4.
Kao H, Chiang S, Chung H, Tsai F, Chen C . Advanced MR imaging of gliomas: an update. Biomed Res Int. 2013; 2013:970586. PMC: 3686060. DOI: 10.1155/2013/970586. View

5.
Valotassiou V, Leondi A, Angelidis G, Psimadas D, Georgoulias P . SPECT and PET imaging of meningiomas. ScientificWorldJournal. 2012; 2012:412580. PMC: 3353476. DOI: 10.1100/2012/412580. View